We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ambry Genetics Reports Results from Clinical Diagnostic Exome™ Testing of Three Patients
News

Ambry Genetics Reports Results from Clinical Diagnostic Exome™ Testing of Three Patients

Ambry Genetics Reports Results from Clinical Diagnostic Exome™ Testing of Three Patients
News

Ambry Genetics Reports Results from Clinical Diagnostic Exome™ Testing of Three Patients

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ambry Genetics Reports Results from Clinical Diagnostic Exome™ Testing of Three Patients"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

“This marks a pivotal moment for clinical diagnostics,” said Charles Dunlop, chief executive officer of Ambry Genetics. “A full diagnostic exome test with a high percentage of diagnosis is potentially a game changer for how clinicians approach diagnostics.  Some of these families have been trying to figure out what was ailing their children for years, and we solved the riddle in weeks. Our exome test is being covered by major national health insurance carriers, making it available to much of the population.  We will be able to help many people suffering from undiagnosed conditions, and nothing makes me more thrilled as a scientist and chief executive."

Ambry Genetics was the first CLIA-certified laboratory to offer whole exome sequencing for clinical diagnostics, and the company believes that its Clinical Diagnostic Exome test is the first to deliver clinical results.  

Wenqi Zeng, PhD., director of clinical genomics at Ambry Genetics added additional perspective, “We’re now finding the cause of the disease much faster because we are able to look into the patients blueprint. This is essentially a human genome project for an individual patient.”

“The Clinical Diagnostic Exome offers hope to those suffering from previously-undiagnosed conditions,” said Elizabeth Chao, M.D., assistant medical director of Ambry Genetics. “We anticipate being able to share more details about these specific cases in the coming weeks.”

Advertisement